Brief: ADC Therapeutics Announces Results From Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine In Relapsed Or Refractory Hodgkin Lymphoma

Adc Therapeutics

10/06/2022 08:04

June 10 (Reuters) - ADC Therapeutics SA  ADCT.N :
    * ADC THERAPEUTICS ANNOUNCES RESULTS FROM PIVOTAL PHASE 2
CLINICAL
TRIAL OF CAMIDANLUMAB TESIRINE (CAMI) IN RELAPSED OR REFRACTORY
HODGKIN LYMPHOMA
    * OVERALL RESPONSE RATE OF 70.1% AND COMPLETE RESPONSE RATE
OF
33.3% IN HEAVILY PRETREATED PATIENTS
    * PREPARING FOR POTENTIAL SUBMISSION OF A BIOLOGICS LICENSE
APPLICATION TO THE FDA
    * SAFETY PROFILE SUBSTANTIALLY CONSISTENT WITH PRIOR
FINDINGS

Source text for Eikon:  ID:nBwKRgcXa 
Further company coverage:  ADCT.N 

 ((Reuters.briefs@thomsonreuters.com;))